NCT06599229View on ClinicalTrials.gov

Perfusion Abnormalities in Hypertrophic Cardiomyopathy

Not yet recruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2028

Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
DIAGNOSTIC_TEST

myocardial contrast echo

Vasodilator stress myocardial contrast echocardiography will be performed at baseline and within 4 months of reaching target dose of a cardiac myosin inhibitor.

All Listed Sponsors
lead

University of Virginia

OTHER

NCT06599229 - Perfusion Abnormalities in Hypertrophic Cardiomyopathy | Biotech Hunter | Biotech Hunter